A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer

A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients

This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.

Inclusion Criteria:

• female patients, 18-70years of age;
• histologically-proven invasive breast cancer;
• no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix;
• no distant disease/secondary cancer.

Exclusion Criteria:

• pregnant or lactating women;
• pre-operative local treatment for breast cancer;
• prior or concurrent systemic antitumor therapy;
• clinically significant cardiac disease.